Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jun;40(6):1448–1453. doi: 10.1128/aac.40.6.1448

In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors.

C J Bacchi 1, R Brun 1, S L Croft 1, K Alicea 1, Y Bühler 1
PMCID: PMC163348  PMID: 8726018

Abstract

A series of novel aromatic derivatives based on the structure of methylglyoxal bis(guanylhydrazone) (MGBG) was examined for trypanocidal activities in human and veterinary trypanosomes of African origin. One agent, CGP 40215A, a bicyclic analog of MGBG which also resembles the diamidines diminazene (Berenil) and pentamidine, was curative of infections by 19 isolates of Trypanosoma brucei subspecies as well as a Trypanosoma congolense isolate. Several of these isolates were resistant to standard trypanocides. Curative doses were < or = 25 mg/kg of body weight/day for 3 days in these acute laboratory model infections. In addition, CGP 40215A also cured a model central nervous system infection in combination with the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine (DFMO; Ornidyl, eflornithine). Curative combinations were 14 days of oral 2% DFMO (approximately 5 g/kg/day) plus 5, 10, or 25 mg/kg/day for 3 or 7 days given by intraperitoneal injection or with a miniosmotic pump. Combinations were most effective if CGP 40215A was given in the second half or at the end of the DFMO regimen. MGBG has modest activity as an inhibitor of trypanosome S-adenosylmethionine decarboxylase (50% inhibitory concentration [IC50]. 130 microM), while CGP 40215A was a more active inhibitor (IC50, 20 microM). Preincubation of trypanosomes with CGP 40215A for 1 h caused a reduction in spermidine content (36%) and an increase in putrescine content (20%), indicating that one possible mechanism of its action may be inhibition of polyamine biosynthesis.

Full Text

The Full Text of this article is available as a PDF (269.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacchi C. J., Garofalo J., Ciminelli M., Rattendi D., Goldberg B., McCann P. P., Yarlett N. Resistance to DL-alpha-difluoromethylornithine by clinical isolates of Trypanosoma brucei rhodesiense. Role of S-adenosylmethionine. Biochem Pharmacol. 1993 Aug 3;46(3):471–481. doi: 10.1016/0006-2952(93)90524-z. [DOI] [PubMed] [Google Scholar]
  2. Bacchi C. J., Nathan H. C., Clarkson A. B., Jr, Bienen E. J., Bitonti A. J., McCann P. P., Sjoerdsma A. Effects of the ornithine decarboxylase inhibitors DL-alpha-difluoromethylornithine and alpha-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models. Am J Trop Med Hyg. 1987 Jan;36(1):46–52. doi: 10.4269/ajtmh.1987.36.46. [DOI] [PubMed] [Google Scholar]
  3. Bacchi C. J., Nathan H. C., Livingston T., Valladares G., Saric M., Sayer P. D., Njogu A. R., Clarkson A. B., Jr Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Antimicrob Agents Chemother. 1990 Jun;34(6):1183–1188. doi: 10.1128/aac.34.6.1183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bacchi C. J., Nathan H. C., Yarlett N., Goldberg B., McCann P. P., Sjoerdsma A., Saric M., Clarkson A. B., Jr Combination chemotherapy of drug-resistant Trypanosoma brucei rhodesiense infections in mice using DL-alpha-difluoromethylornithine and standard trypanocides. Antimicrob Agents Chemother. 1994 Mar;38(3):563–569. doi: 10.1128/aac.38.3.563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bales J. D., Jr, Harrison S. M., Mbwabi D. L., Schecter P. J. Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya. Ann Trop Med Parasitol. 1989 Aug;83 (Suppl 1):111–114. doi: 10.1080/00034983.1989.11812414. [DOI] [PubMed] [Google Scholar]
  6. Bitonti A. J., Bacchi C. J., McCann P. P., Sjoerdsma A. Catalytic irreversible inhibition of Trypanosoma brucei brucei ornithine decarboxylase by substrate and product analogs and their effects on murine trypanosomiasis. Biochem Pharmacol. 1985 May 15;34(10):1773–1777. doi: 10.1016/0006-2952(85)90648-3. [DOI] [PubMed] [Google Scholar]
  7. Bitonti A. J., Byers T. L., Bush T. L., Casara P. J., Bacchi C. J., Clarkson A. B., Jr, McCann P. P., Sjoerdsma A. Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase. Antimicrob Agents Chemother. 1990 Aug;34(8):1485–1490. doi: 10.1128/aac.34.8.1485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brun R., Bühler Y., Sandmeier U., Kaminsky R., Bacchi C. J., Rattendi D., Lane S., Croft S. L., Snowdon D., Yardley V. In vitro trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors. Antimicrob Agents Chemother. 1996 Jun;40(6):1442–1447. doi: 10.1128/aac.40.6.1442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. CUNNINGHAM M. P., VICKERMAN K. Antigenic analysis in the Trypanosoma brucei group, using the agglutination reaction. Trans R Soc Trop Med Hyg. 1962 Jan;56:48–59. doi: 10.1016/0035-9203(62)90088-3. [DOI] [PubMed] [Google Scholar]
  10. Carter N. S., Berger B. J., Fairlamb A. H. Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. J Biol Chem. 1995 Nov 24;270(47):28153–28157. doi: 10.1074/jbc.270.47.28153. [DOI] [PubMed] [Google Scholar]
  11. Clarkson A. B., Jr, Bienen E. J., Bacchi C. J., McCann P. P., Nathan H. C., Hutner S. H., Sjoerdsma A. New drug combination for experimental late-stage African trypanosomiasis: DL-alpha-difluoromethylornithine (DFMO) with suramin. Am J Trop Med Hyg. 1984 Nov;33(6):1073–1077. doi: 10.4269/ajtmh.1984.33.1073. [DOI] [PubMed] [Google Scholar]
  12. Fairlamb A. H., Carter N. S., Cunningham M., Smith K. Characterisation of melarsen-resistant Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Mol Biochem Parasitol. 1992 Jul;53(1-2):213–222. doi: 10.1016/0166-6851(92)90023-d. [DOI] [PubMed] [Google Scholar]
  13. Hölttä E., Hannonen P., Pispa J., Jänne J. Effect of methylglyoxal bis(guanylhydrazone) on polyamine metabolism in normal and regenerating rat liver and rat thymus. Biochem J. 1973 Nov;136(3):669–676. doi: 10.1042/bj1360669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jennings F. W. Chemotherapy of CNS-trypanosomiasis: the combined use of diminazene aceturate or pentamidine with DL-alpha-difluoromethylornithine (DFMO). Trop Med Parasitol. 1992 Jun;43(2):106–109. [PubMed] [Google Scholar]
  15. Jennings F. W., Gray G. D. Relapsed parasitaemia following chemotherapy of chronic T. brucei infections in mice and its relation to cerebral trypanosomes. Contrib Microbiol Immunol. 1983;7:147–154. [PubMed] [Google Scholar]
  16. Jennings F. W. The potentiation of arsenicals with difluoromethylornithine (DFMO): experimental studies in murine trypanosomiasis. Bull Soc Pathol Exot Filiales. 1988;81(3 Pt 2):595–607. [PubMed] [Google Scholar]
  17. Jennings F. W., Whitelaw D. D., Urquhart G. M. The relationship between duration of infection with Trypanosoma brucei in mice and the efficacy of chemotherapy. Parasitology. 1977 Oct;75(2):143–153. doi: 10.1017/s0031182000062284. [DOI] [PubMed] [Google Scholar]
  18. Mehlitz D., Brinkmann U., Haller L. Epidemiological studies on the animal reservoir of gambiense sleeping sickness. Part I. Review of literature and description of the study areas. Tropenmed Parasitol. 1981 Sep;32(3):129–133. [PubMed] [Google Scholar]
  19. Pegg A. E. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res. 1988 Feb 15;48(4):759–774. [PubMed] [Google Scholar]
  20. Regenass U., Caravatti G., Mett H., Stanek J., Schneider P., Müller M., Matter A., Vertino P., Porter C. W. New S-adenosylmethionine decarboxylase inhibitors with potent antitumor activity. Cancer Res. 1992 Sep 1;52(17):4712–4718. [PubMed] [Google Scholar]
  21. Regenass U., Mett H., Stanek J., Mueller M., Kramer D., Porter C. W. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity. Cancer Res. 1994 Jun 15;54(12):3210–3217. [PubMed] [Google Scholar]
  22. Stanek J., Caravatti G., Capraro H. G., Furet P., Mett H., Schneider P., Regenass U. S-adenosylmethionine decarboxylase inhibitors: new aryl and heteroaryl analogues of methylglyoxal bis(guanylhydrazone). J Med Chem. 1993 Jan 8;36(1):46–54. doi: 10.1021/jm00053a007. [DOI] [PubMed] [Google Scholar]
  23. Van Nieuwenhove S. Advances in sleeping sickness therapy. Ann Soc Belg Med Trop. 1992;72 (Suppl 1):39–51. [PubMed] [Google Scholar]
  24. Warrell R. P., Jr, Burchenal J. H. Methylglyoxal-bis(guanylhydrazone) (Methyl-GAG): current status and future prospects. J Clin Oncol. 1983 Jan;1(1):52–65. doi: 10.1200/JCO.1983.1.1.52. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES